



Published in final edited form as:

J Neural Transm (Vienna). 2019 December ; 126(12): 1707–1711. doi:10.1007/s00702-019-02086-w.

Association between cognitive performance and *SYT1*-rs2251214 among women with cocaine use disorder

Thiago Wendt Viola¹, Jaqueline Bohrer Schuch², Diego Luiz Rovaris^{3,4}, Rafael Genovese¹, Lucca Tondo¹, Breno Sanvicente-Vieira⁵, Aline Zaparte¹, Renata Cupertino^{4,6}, Bruna Santos da Silva^{4,6}, Claiton Henrique Dotto Bau^{4,6}, Rodrigo Grassi-Oliveira¹

¹Developmental Cognitive Neuroscience Lab, School of Health Sciences, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil

²Center for Drug and Alcohol Research, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

³Department of Psychiatry, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Rio Grande do Sul, Porto Alegre, Brazil

⁴ADHD Outpatient Program, Adult Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

⁵Department of Psychology, Pontifícia Universidade Católica do Rio de Janeiro, Rio de Janeiro, Brazil

⁶Department of Genetics, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

Abstract

The SNP rs2251214 of the *SYT1* gene was recently associated with externalizing phenotypes, including ADHD and cocaine use disorder (CUD). Here, we investigated whether *SYT1*-rs2251214 could also be implicated with cognitive performance variations among women with CUD. Results showed that G homozygous ($n = 146$) have lower cognitive performance in the Stroop, Trail Making and Matrix Reasoning tests compared with A-allele carriers ($n = 64$), suggesting that rs2251214 may influence the severity of cognitive impairments in CUD.

Keywords

SNARE complex; Cocaine Addiction; Substance use disorders; Stimulants; Cognition

Corresponding author: Rodrigo Grassi-Oliveira, rodrigo.grassi@pucrs.br, *Address:* PUCRS, Avenida Ipiranga 6690 – Prédio 63; Jardim Botânico – Porto Alegre, RS, Brasil.

Publisher's Disclaimer: This Author Accepted Manuscript is a PDF file of an unedited peer-reviewed manuscript that has been accepted for publication but has not been copyedited or corrected. The official version of record that is published in the journal is kept up to date and so may therefore differ from this version.

Conflict of Interest: The authors declare that they have no conflict of interest.

1. Introduction

Cocaine use disorder (CUD) is associated with cognitive deficits. A meta-analytic review comprising 1452 CUD patients and 1411 controls demonstrated deficits across 8 cognitive domains with larger effect sizes related to attention, impulsivity, learning/memory, working memory and inhibitory control (Potvin et al. 2014). Such impairments remain stable during the first months of abstinence, although evidence suggests improvements in cognition of CUD patients after sustained abstinence (Mahoney 2019). Cognitive dysfunction in CUD has been shown to be closely linked to negative clinical outcomes, such as lack of treatment adherence, as well as with higher relapse rates (Nuijten et al. 2016; Sofuoglu et al. 2016). However, genetic factors influencing the effects of chronic cocaine use on cognition are not fully understood.

The SNARE (soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptors) complex plays a key role in the brain by controlling neurotransmitter release (Ramakrishnan et al. 2012). Synaptotagmin I (SYT1) is a synaptic vesicle protein that functions as a calcium sensor and is a main regulator of the SNARE complex. Convincing preclinical data have showed that SYT1 expression correlates with cognitive measures and neuronal function in rodents (Baliotti et al. 2018; Jia et al. 2010; Chen et al. 2013; Zhang et al. 2017; Yu et al. 2018). Recently, human genome-wide association studies (GWAS) have identified associated SNPs on *SYT1* gene with personality traits as neuroticism (Luciano et al. 2018), and with educational attainment and cognitive performance (Lee et al. 2018). Furthermore, a recent GWAS of 300,486 non-demented individuals found that *SYT1* is among many genes influencing general cognitive ability (Davies et al. 2018).

A specific variant, *SYT1*-rs2251214, was recently associated with methylphenidate treatment response variability in ADHD (da Silva et al. 2018) and with the susceptibility to develop CUD (da Silva et al. 2019) in candidate gene studies. However, the role of *SYT1*-rs2251214 on cognitive phenotypes of substance use disorders remains to be elucidated. Therefore, in this study we investigated whether *SYT1*-rs2251214 could also be implicated with cognitive performance variations among women with CUD.

2. Material and Methods

2.1. Participants

This cross-sectional study was performed in female patients with CUD undergoing treatment in an inpatient detoxification unit of a public hospital in Southern Brazil. Hospitalization for drug detoxification is one of the treatment options available in the public health-care system in Brazil. Included participants ($n = 210$) met the following criteria: (1) age of 18 to 60 years old; (2) diagnosis of CUD according to Structured Clinical Interview for DSM-5 (SCID) (American Psychiatric Association 2010); (3) self-report of smoked or snorted cocaine as the most harmful substance with regard to drug-related problems; and (4) absence of psychotic syndromes and other severe medical condition. The current research was approved by the Ethical Committee of the enrolled institutions, and all of the participants provided written informed consent.

2.2. Study procedures and cognitive assessment

The detoxification treatment takes 21 days and participants were invited to take part in the study during the first 3 days after treatment enrollment. Participants were treated in an inpatient abstinence controlled environment, so they had no access to alcohol, nicotine or other drugs. Prescribed symptomatic cocaine detoxification protocol was applied during treatment, including neuroleptics, analgesics, antidepressants and mood stabilizers. Benzodiazepines were not prescribed.

Within the first week, clinical characteristics of participants were assessed through the Addiction Severity Index 6 (ASI-6) (Kessler et al. 2012; Cacciola et al. 2011). The ASI-6 is a semi-structured interview and it was used to assess recent substance use (e.g. cocaine, alcohol, cannabis and tobacco), as well as lifetime problems in the following domains: psychiatric, alcohol, legal, medical, employment, and family and social support. The presence of polysubstance use was defined as having consumed 10 or more times other substances during the last 30 days before treatment enrollment.

The battery of tests was designed to assess multiple cognitive components, including verbal knowledge, reasoning, verbal fluency, inhibition, cognitive flexibility, visual attention, processing speed and selective attention. In order to reduce any possible bias in cognitive tasks due to abstinence symptoms, the cognitive battery was administered individually over 2 sessions, when participants were no longer in the acute phases of drug withdrawal (defined as the first 72 hours of abstinence, Potvin et al. 2014). No sedative medication was administered for 24 hours before cognitive assessment.

The first session was carried out approximately 10 days after participant's enrollment in the treatment program. In this session, the Vocabulary subtest of the Wechsler Abbreviated Scale of Intelligence (WASI) (Heck and Trentini 2009) was used to assess verbal knowledge, and the Matrix Reasoning subtest of the WASI was used to assess reasoning capabilities. No participants had early treatment discharge at this point, resulting in a sample size of 210 for these analyses.

The second session was performed approximately 15 days after treatment enrollment. The Trail Making Test B assessed cognitive flexibility, visual attention and processing speed (Campanholo et al. 2014), and the Stroop Color-Word Interference Test – Golden Version measured the domains of selective attention and inhibitory control (Zimmermann et al. 2015). The Verbal Fluency Task assessed phonemic and semantic verbal fluency (Bertola et al. 2014). Sixteen participants had early treatment discharge, resulting in a sample size of 194 for these analyses. Patients were voluntarily included in the treatment program, thus they were allowed to request early discharge.

2.3. Genotyping

DNA extraction from peripheral blood was performed by salting out as described in Lahiri and Nurnberger (Lahiri and Nurnberger 1991). *SYT1*-rs2251214 was genotyped by TaqMan allelic discrimination assay (Applied Biosystems StepOne Real Time PCR System) according to the manufacturer's suggested protocol. Approximately, 10% of the sample was re-genotyped, aiming quality control, and no genotyping inconsistencies were found.

2.4. Statistical analyses

Data was tested for normality of distribution by Shapiro–Wilk test. The demographic, clinical and cognitive measures were examined using Chi-Squared tests, or independent *t*-tests comparing groups with CUD subdivided according to *SYTI*-rs2251214. Heterozygotes and homozygotes for the minor allele were assembled and compared to homozygotes for the major allele (A-carriers versus GG). For each cognitive task the dominant genetic model was tested using SNPAssoc R package (version 1.9–2). We tested for possible confounders, however, none of the variables tested (table 1) was included as a covariate since they were not associated with both the study factor and outcomes (Cordell 2009).

3. Results

Demographic and clinical data of are depicted in Table 1. No significant differences were detected on these measures between A-carriers versus GG. Overall means of cognitive measures are depicted in Table 2. Association analyses showed an effect of *SYTI*-rs2251214 on Matrix Reasoning score ($p = 0.011$), on Stroop score ($p = 0.019$) and on Trail Making Test B score ($p = 0.042$). GG-genotype was associated with lower performance in these cognitive tests among women with CUD. No significant effects of *SYTI*-rs2251214 on the remaining cognitive measures were observed.

4. Discussion

In this study we showed that *SYTI*-rs2251214 GG was associated with lower cognitive performance in reasoning, selective attention, inhibitory control, cognitive flexibility, visual attention and processing speed domains compared with A-carriers. These cognitive domains have a key role in behavioral adaptation and self-control among substance abusers (Sullivan et al. 2018). Although CUD is associated with cognitive impairments *per se*, this finding indicates that *SYTI*-rs2251214 may also influence the severity of cognitive impairments among female cocaine users. Moreover, it is possible that the cognitive alterations associated with this SNP may contribute to increase the risk for the development of CUD, considering the association between *SYTI*-rs2251214 GG genotype and CUD found in a previous case-control study (da Silva et al. 2019). This hypothesis corroborates the idea that cocaine users may present cognitive deficits predating the onset of cocaine use (Spronk et al. 2013).

Indeed, this SNP has been associated with neuropsychiatric disorders in which reduced cognitive and executive functioning performance are key features. The G allele of rs2251214 was associated with ADHD susceptibility (Cupertino et al. 2017) and more recently with methylphenidate poor treatment response, specifically in the domains of inattention and oppositional defiant symptoms (da Silva et al. 2018). This SNP had also an effect on the age at onset of impairment due to ADHD and other externalizing disorders (Cupertino et al. 2017). Although the molecular mechanisms by which rs2251214 could affect cognition are still unknown, preclinical evidence supports the role of *SYTI* on brain functioning given that CRISPRi tools that silence *SYTI* also impaired the balance between inhibitory and excitatory synapses (Zheng et al. 2018).

This study should be interpreted in the context of some limitations. First, considering that participants were recruited by convenience sampling in a women's psychiatric unit, we cannot generalize these findings to male samples. Second, participants with CUD also presented a history of alcohol, tobacco and cannabis use, which might interfere in cognitive performance as well. Despite that individuals with drug addiction commonly report the consumption of multiple drugs (Aharonovich et al. 2005; Viola et al. 2014), the frequency of polysubstance use was similar among GG and A-carriers. Third, this study had a small sample size; however, it is important to highlight the difficulty in perform multiple levels of assessment (e.g. cognitive, clinical and genetic) in individuals with CUD. Future studies, with larger samples and addressing the molecular effects of *SYT1*-rs2251214 on cognition and substance use disorders are warranted.

These findings fit well with a growing body of evidence, including GWAS findings, showing that SNPs in genes implicated with neurotransmitter release are important factors accounting for on cognition and externalizing phenotypes.

Acknowledgements:

This study was funded by MCT/CT-Saúde—DECIT/SCTIE/MS, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (Grant number 466802/2014–5), Secretaria Nacional de Políticas sobre Drogas (SENAD) / Ministério da Justiça (Grant number 822647/2015). This study was also financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) – Finance Code 001. This work was partially funded by National Institute on Drug Abuse (NIDA) grant R01DA044859. The funding source had no involvement in study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication. The authors would like to thank all members of the Sistema de Saúde Mãe de Deus.

Funding: This study was funded by MCT/CT-Saúde—DECIT/SCTIE/MS, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (Grant number 466802/2014–5), Secretaria Nacional de Políticas sobre Drogas (SENAD) / Ministério da Justiça (Grant number 822647/2015). This study was also financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) – Finance Code 001. This work was partially funded by National Institute on Drug Abuse (NIDA) grant R01DA044859. The funding source had no involvement in study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication.

References

- Aharonovich E, Liu X, Samet S, Nunes E, Waxman R, Hasin D (2005) Postdischarge cannabis use and its relationship to cocaine, alcohol, and heroin use: a prospective study. *Am J Psychiatry* 162 (8): 1507–1514. 10.1176/appi.ajp.162.8.1507 [PubMed: 16055773]
- American Psychiatric Association (2010) DSM-V Prelude Project. www.dsm5.org. Accessed October 07 2010
- Baliotti M, Fattorini G, Pugliese A, Marcotulli D, Bragina L, Conti F (2018) Two Behavioral Tests Allow a Better Correlation Between Cognitive Function and Expression of Synaptic Proteins. *Front Aging Neurosci* 10:91 10.3389/fnagi.2018.00091 [PubMed: 29670520]
- Bertola L, Mota NB, Copelli M, Rivero T, Diniz BS, Romano-Silva MA, Ribeiro S, Malloy-Diniz LF (2014) Graph analysis of verbal fluency test discriminate between patients with Alzheimer's disease, mild cognitive impairment and normal elderly controls. *Front Aging Neurosci* 6:185 10.3389/fnagi.2014.00185 [PubMed: 25120480]
- Cacciola JS, Alterman AI, Habing B, McLellan AT (2011) Recent status scores for version 6 of the Addiction Severity Index (ASI –6). *Addiction* 106 (9):1588–1602. 10.1111/j.1360-0443.2011.03482.x [PubMed: 21545666]
- Campanholo KR, Romão MA, Machado MAR, Serrao VT, Coutinho DGC, Benute GRG, Miotto EC, de Lucia MCS (2014) Performance of an adult Brazilian sample on the Trail Making Test and

Stroop Test. *Dement Neuropsychol* 8 (1):26–31. 10.1590/S1980-57642014DN81000005 [PubMed: 29213876]

- Chen G, Hu T, Wang Z, Li Q, Li J, Jia Y, Xu WH (2013) Down-regulation of synaptotagmin 1 in cortex, hippocampus, and cerebellum after experimental subarachnoid hemorrhage. *Ann Clin Lab Sci* 43 (3):250–256 [PubMed: 23884218]
- Cordell HJ (2009) Detecting gene-gene interactions that underlie human diseases. *Nat Rev Genet* 10 (6):392–404. 10.1038/nrg2579 [PubMed: 19434077]
- Cupertino RB, Schuch JB, Bandeira CE, da Silva BS, Rovaris DL, Kappel DB, Contini V, Salatino-Oliveira A, Vitola ES, Karam RG, Hutz MH, Rohde LA, Grevet EH, Bau CHD, Mota NR (2017) Replicated association of Synaptotagmin (SYT1) with ADHD and its broader influence in externalizing behaviors. *Eur Neuropsychopharmacol* 27 (3):239–247. 10.1016/j.euroneuro.2017.01.007 [PubMed: 28130000]
- da Silva BS, Cupertino RB, Rovaris DL, Schuch JB, Kappel DB, Müller D, Bandeira CE, Victor MM, Karam RG, Mota NR, Rohde LA, Contini V, Grevet EH, Bau CHD (2018) Exocytosis-related genes and response to methylphenidate treatment in adults with ADHD. *Mol Psychiatry* 23 (6): 1446–1452. 10.1038/mp.2017.90 [PubMed: 28461697]
- da Silva BS, Cupertino RB, Schuch JB, Kappel DB, Sanvicente-Vieira B, Bandeira CE, von Diemen L, Kessler FHP, Grevet EH, Grassi-Oliveira R, Bau CHD, Rovaris DL (2019) The association between SYT1-rs2251214 and cocaine use disorder further supports its role in psychiatry. *Prog Neuropsychopharmacol Biol Psychiatry* 94:109642 10.1016/j.pnpbp.2019.109642 [PubMed: 31059723]
- Davies G, Lam M, Harris SE, Trampush JW, Luciano M, Hill WD, Hagenaars SP, Ritchie SJ, Marioni RE, Fawns-Ritchie C, Liewald DCM, Okely JA, Ahola-Olli AV, Barnes CLK, Bertram L, Bis JC, Burdick KE, Christoforou A, DeRosse P, Djurovic S, Espeseth T, Giakoumaki S, Giddaluru S, Gustavson DE, Hayward C, Hofer E, Ikram MA, Karlsson R, Knowles E, Lahti J, Leber M, Li S, Mather KA, Melle I, Morris D, Oldmeadow C, Palviainen T, Payton A, Pazoki R, Petrovic K, Reynolds CA, Sargurupremraj M, Scholz M, Smith JA, Smith AV, Terzikhan N, Thalamuthu A, Trompet S, van der Lee SJ, Ware EB, Windham BG, Wright MJ, Yang J, Yu J, Ames D, Amin N, Amouyel P, Andreassen OA, Armstrong NJ, Assareh AA, Attia JR, Attix D, Avramopoulos D, Bennett DA, Böhmer AC, Boyle PA, Brodaty H, Campbell H, Cannon TD, Cirulli ET, Congdon E, Conley ED, Corley J, Cox SR, Dale AM, Dehghan A, Dick D, Dickinson D, Eriksson JG, Evangelou E, Faul JD, Ford I, Freimer NA, Gao H, Giegling I, Gillespie NA, Gordon SD, Gottesman RF, Griswold ME, Gudnason V, Harris TB, Hartmann AM, Hatzimanolis A, Heiss G, Holliday EG, Joshi PK, Kähönen M, Kardina SLR, Karlsson I, Kleindam L, Knopman DS, Kochan NA, Konte B, Kwok JB, Le Hellard S, Lee T, Lehtimäki T, Li SC, Liu T, Koini M, London E, Longstreth WT, Lopez OL, Loukola A, Luck T, Lundervold AJ, Lundquist A, Lytikäinen LP, Martin NG, Montgomery GW, Murray AD, Need AC, Noordam R, Nyberg L, Ollier W, Papenberg G, Pattie A, Polasek O, Poldrack RA, Psaty BM, Reppermund S, Riedel-Heller SG, Rose RJ, Rotter JI, Roussos P, Rovio SP, Saba Y, Sabb FW, Sachdev PS, Satizabal CL, Schmid M, Scott RJ, Scult MA, Simino J, Slagboom PE, Smyrnis N, Soumaré A, Stefanis NC, Stott DJ, Straub RE, Sundet K, Taylor AM, Taylor KD, Tzoulaki I, Tzourio C, Uitterlinden A, Vitart V, Voineskos AN, Kaprio J, Wagner M, Wagner H, Weinhold L, Wen KH, Widen E, Yang Q, Zhao W, Adams HHH, Arking DE, Bilder RM, Bitsios P, Boerwinkle E, Chiba-Falek O, Corvin A, De Jager PL, Debette S, Donohoe G, Elliott P, Fitzpatrick AL, Gill M, Glahn DC, Hägg S, Hansell NK, Hariri AR, Ikram MK, Jukema JW, Vuoksima E, Keller MC, Kremen WS, Launer L, Lindenberger U, Palotie A, Pedersen NL, Pendleton N, Porteous DJ, Rääkkönen K, Raitakari OT, Ramirez A, Reinvang I, Rudan I, Rujescu Dan, Schmidt R, Schmidt H, Schofield PW, Schofield PR, Starr JM, Steen VM, Trollor JN, Turner ST, Van Duijn CM, Villringer A, Weinberger DR, Weir DR, Wilson JF, Malhotra A, McIntosh AM, Gale CR, Seshadri S, Mosley TH, Bressler J, Lencz T, Deary IJ (2018) Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. *Nat Commun* 9 (1):2098 10.1038/s41467-018-04362-x [PubMed: 29844566]
- Heck VS, Trentini CM (2009) [Intelligence: psychometric theory and adaptation of the verbal subtests of the WASI scale to Brazilian Portuguese]. Universidade Federal do Rio Grande do Sul, Porto Alegre-RS, Brazil

- Jia N, Yang K, Sun Q, Cai Q, Li H, Cheng D, Fan X, Zhu Z (2010) Prenatal stress causes dendritic atrophy of pyramidal neurons in hippocampal CA3 region by glutamate in offspring rats. *Dev Neurobiol* 70 (2):114–125. 10.1002/dneu.20766 [PubMed: 19950194]
- Kessler F, Cacciola J, Alterman A, Faller S, Souza-Formigoni ML, Cruz MS, Brasiliano S, Pechansky F (2012) Psychometric properties of the sixth version of the Addiction Severity Index (ASI-6) in Brazil. *Rev Bras Psiquiatr* 34 (1):24–33 [PubMed: 22392385]
- Lahiri DK, Nurnberger JI (1991) A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. *Nucleic Acids Res* 19 (19):5444 [PubMed: 1681511]
- Lee JJ, Wedow R, Okbay A, Kong E, Maghziyan O, Zacher M, Nguyen-Viet TA, Bowers P, Sidorenko J, Karlsson Linnér R, Fontana MA, Kundu T, Lee C, Li H, Li R, Royer R, Timshel PN, Walters RK, Willoughby EA, Yengo L, Alver M, Bao Y, Clark DW, Day FR, Furlotte NA, Joshi PK, Kemper KE, Kleinman A, Langenberg C, Mägi R, Trampush JW, Verma SS, Wu Y, Lam M, Zhao JH, Zheng Z, Boardman JD, Campbell H, Freese J, Harris KM, Hayward C, Herd P, Kumari M, Lencz T, Luan J, Malhotra AK, Metspalu A, Milani L, Ong KK, Perry JRB, Porteous DJ, Ritchie MD, Smart MC, Smith BH, Tung JY, Wareham NJ, Wilson JF, Beauchamp JP, Conley DC, Esko T, Lehrer SF, Magnusson PKE, Oskarsson S, Pers TH, Robinson MR, Thom K, Watson C, Chabris CF, Meyer MN, Laibson DI, Yang J, Johannesson M, Koellinger PD, Turley P, Visscher PM, Benjamin DJ, Cesarini D, Team aR, Consortium CCG, Consortium SSGA (2018) Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. *Nat Genet* 50 (8):1112–1121. 10.1038/s41588-018-0147-3 [PubMed: 30038396]
- Luciano M, Hagenaars SP, Davies G, Hill WD, Clarke TK, Shirali M, Harris SE, Marioni RE, Liewald DC, Fawns-Ritchie C, Adams MJ, Howard DM, Lewis CM, Gale CR, McIntosh AM, Deary IJ (2018) Association analysis in over 329,000 individuals identifies 116 independent variants influencing neuroticism. *Nat Genet* 50 (1):6–11. 10.1038/s41588-017-0013-8 [PubMed: 29255261]
- Mahoney JJ (2019) Cognitive dysfunction in individuals with cocaine use disorder: Potential moderating factors and pharmacological treatments. *Exp Clin Psychopharmacol* 27 (3):203–214. 10.1037/pha0000245 [PubMed: 30556731]
- Nuijten M, Blanken P, Van den Brink W, Goudriaan AE, Hendriks VM (2016) Impulsivity and attentional bias as predictors of modafinil treatment outcome for retention and drug use in crack-cocaine dependent patients: Results of a randomised controlled trial. *J Psychopharmacol* 30 (7):616–626. 10.1177/0269881116645268 [PubMed: 27147591]
- Potvin S, Stavro K, Rizkallah E, Pelletier J (2014) Cocaine and cognition: a systematic quantitative review. *J Addict Med* 8 (5):368–376. 10.1097/ADM.000000000000066 [PubMed: 25187977]
- Ramakrishnan NA, Drescher MJ, Drescher DG (2012) The SNARE complex in neuronal and sensory cells. *Mol Cell Neurosci* 50 (1):58–69. 10.1016/j.mcn.2012.03.009 [PubMed: 22498053]
- Sofuoglu M, DeVito EE, Waters AJ, Carroll KM (2016) Cognitive Function as a Transdiagnostic Treatment Target in Stimulant Use Disorders. *J Dual Diagn* 12 (1):90–106. 10.1080/15504263.2016.1146383 [PubMed: 26828702]
- Sprong DB, van Wel JH, Ramaekers JG, Verkes RJ (2013) Characterizing the cognitive effects of cocaine: a comprehensive review. *Neurosci Biobehav Rev* 37 (8):1838–1859. 10.1016/j.neubiorev.2013.07.003 [PubMed: 23876288]
- Sullivan RM, Perlman G, Moeller SJ (2018) Meta-analysis of aberrant post-error slowing in substance use disorder: implications for behavioral adaptation and self-control. *Eur J Neurosci*. 10.1111/ejn.14229
- Viola TW, Tractenberg SG, Wearick-Silva LE, Rosa CS, Pezzi JC, Grassi-Oliveira R (2014) Long-term cannabis abuse and early-onset cannabis use increase the severity of cocaine withdrawal during detoxification and rehospitalization rates due to cocaine dependence. *Drug Alcohol Depend* 144:153–159. 10.1016/j.drugalcdep.2014.09.003 [PubMed: 25262527]
- Yu H, Yang X, Tang X, Tang R (2018) Effects of spontaneous recurrent seizures on cognitive function via modulation of SNAREs expression. *Int J Neurosci* 128 (4):376–383. 10.1080/00207454.2017.1387115 [PubMed: 29057696]
- Zhang S, Li X, Wang Z, Liu Y, Gao Y, Tan L, Liu E, Zhou Q, Xu C, Wang X, Liu G, Chen H, Wang JZ (2017) Paternal spatial training enhances offspring's cognitive performance and synaptic plasticity

in wild-type but not improve memory deficit in Alzheimer's mice. *Sci Rep* 7 (1):1521 10.1038/s41598-017-01811-3 [PubMed: 28484240]

Zheng Y, Shen W, Zhang J, Yang B, Liu YN, Qi H, Yu X, Lu SY, Chen Y, Xu YZ, Li Y, Gage FH, Mi S, Yao J (2018) CRISPR interference-based specific and efficient gene inactivation in the brain. *Nat Neurosci* 21 (3):447–454. 10.1038/s41593-018-0077-5 [PubMed: 29403034]

Zimmermann N, Cardoso CO, Trentini CM, Grassi-Oliveira R, Fonseca RP (2015) Brazilian preliminary norms and investigation of age and education effects on the Modified Wisconsin Card Sorting Test, Stroop Color and Word test and Digit Span test in adults. *Dement Neuropsychol* 9 (2):120–127. 10.1590/1980-57642015DN92000006 [PubMed: 29213953]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1.Demographic and clinical data of groups with CUD subdivided by *SYTI*-rs2251214 genotype.

	GG (<i>n</i> = 146)	A-carriers (<i>n</i> = 64)	Statistics	<i>p</i> -value
Age (years)	30.75 (8.2)	30.18 (7.0)	<i>t</i> = 0.48	0.627
Educational level			$\chi^2 = 1.01$	0.200
Did not enroll high school	76.1% (<i>n</i> = 108)	69.4% (<i>n</i> = 43)		
Enrolled or finished high school	23.9% (<i>n</i> = 34)	30.6% (<i>n</i> = 19)		
Ethnicity			$\chi^2 = 1.04$	0.194
White	31.3% (<i>n</i> = 46)	38.5% (<i>n</i> = 25)		
Non-white	68.7% (<i>n</i> = 101)	61.5% (<i>n</i> = 40)		
Recent polysubstance chronic use				
Alcohol	25.0% (<i>n</i> = 37)	24.6% (<i>n</i> = 16)	$\chi^2 = 0.04$	0.549
Cannabis	18.9% (<i>n</i> = 28)	21.5% (<i>n</i> = 14)	$\chi^2 = 0.19$	0.394
Tobacco	96.5% (<i>n</i> = 141)	96.8% (<i>n</i> = 62)	$\chi^2 = 0.28$	0.867
Addiction Severity Index 6 scores				
Alcohol	48.41 (9.5)	48.58 (10.3)	<i>t</i> = 0.14	0.888
Psychiatric	49.34 (8.9)	50.26 (9.1)	<i>t</i> = 0.84	0.400
Medical	48.61 (8.6)	48.53 (8.0)	<i>t</i> = 0.06	0.945
Legal	53.01 (8.1)	52.06 (7.2)	<i>t</i> = 0.96	0.338
Employment	37.83 (3.9)	38.46 (4.46)	<i>t</i> = 1.27	0.204
Family and social support	39.68 (8.4)	38.44 (9.0)	<i>t</i> = 1.16	0.246
Psychiatric medication use (daily)	19.6% (<i>n</i> = 29)	21.5% (<i>n</i> = 14)	$\chi^2 = 0.10$	0.439

Legend: Data presented in mean and standard deviation, or percentage and number of participants.

Table 2.

Overall means of cognitive measures and parameters of the association analyses.

Outcome	GG mean (SE)	A-carriers mean (SE)	<i>p</i> -value
Vocabulary	37.42 (1.02)	38.25 (1.19)	0.637
Matrix Reasoning	15.12 (0.51)	17.52 (0.77)	0.011
Stroop	26.29 (0.80)	29.69 (1.27)	0.019
Trail Making	153.8 (5.91)	133.5 (7.80)	0.042
Verbal Fluency	39.37 (1.03)	40.92 (1.35)	0.416

Legend: Data presented in mean and standard error. Vocabulary score was the sum of points in the test. Matrix Reasoning score was the number of correct answers in the test. Stroop score was the number of correct colors named during 45 seconds in the color-word condition. Trail Making score was the time needed to finish the test B. Verbal Fluency score was the sum of the words produced in each stage of the task and a final score that represented the sum of all of the words produced during the task.